18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT

Aim: To compare¹⁸F-FDG PET/CT and¹⁸F-NaF PET/CT with respect to disease prognostication and outcome in patients affected by bone metastases from breast cancer (BC). Patients, methods: We retrospectively investigated 32 women with BC and documented bone metastases. Semi-quantitative parameters were applied to¹⁸F-FDG PET/CT and¹⁸F-Na PET/CT in order to evaluate disease extent and tumour metabolism. We used time-to-event analyses (Kaplan Meier and COX proportional hazard methods) to estimate progression-free (PFS) and overall survival (OS) in order to assess the independent prognostic value of¹⁸F-FDG PET/CT and¹⁸F-Na PET/CT. Results: The sensitivity of¹⁸F-NaF PET/CT (100%) was higher (p < 0.05) than that of¹⁸F-FDG PET/CT (72% and 72%). None of the¹⁸F-FDG PET/CT-negative patients showed disease progression at the end of follow-up. After adjustment for age, Ki-67 levels, presence of visceral metastases, hormone therapy, duration of bone disease and response to first-line therapy, only¹⁸F-FDG SUV mean [HR 15.7, 95% confidence interval (CI) 1.15-214.5] and¹⁸F-FDG whole-body bone metabolic burden (WB-B-MB) (HR 16.9; 95%CI 1.87-152.2) were independently and significantly associated with OS. None of the¹⁸F-NaF PET/CT parameters were associated with OS. None of the conventional clinical prognostic parameters remained significantly associated with OS after the inclusion of PET/ CT parameters in the model. Conclusion:¹⁸F-FDG PET/CT is independently associated with OS in BC patients with bone metastases and its prognostic impact seems to be higher than conventional clinical and biological rognostic factors. Although¹8F-NaF PET/CT has a higher diagnostic sensitivity than¹⁸F-FDG PET/ CT, it is not independently associated with OS.